Why Pharma Marketing Campaigns Fail: The Cost of Internal Approval

In pharma, when the Marketing Head asks the brand manager why the promo material is not yet dispatched, the answer is almost always the same. 'Internal approval is taking time.' It is the most useful sentence in pharma marketing. Not because it is true. Most of the time, it is partly true. But because it stops the conversation. Marketing Head accepts it. Brand manager moves on. Two weeks later, when the same question comes up again, the same sentence works again. Nobody asks the next question. The question is simple. 'How many times has this visual aid gone back for changes?' In PMT review meetings across pharma, that question almost never gets asked. That question changes everything. Because the honest answer, three or five or eleven, opens up a different conversation. Not about how slow medical are. About how many of those rounds could have been avoided before the first draft was even sent. The claim that was not properly supported. The reference that was three years out of date. The copy that no doctor would actually believe. The visual that medical was guaranteed to flag. Every one of these is easy to spot on day one. None of them are caught on day one. Not because the brand manager is careless, but because the brand manager is alone. There is no role in the team whose job it is to ask, 'will this survive medical, regulatory and legal?', before the visual aid leaves the desk. So the brand manager keeps moving. The next deck, the next campaign, the next quarterly review. And the rejection rounds keep arriving. So the same visual aid goes back. And back. And back. Each round, one campaign date moves by ten days. Across a portfolio of ten brands, each going through three to five rounds a year, that is months of brand momentum lost every year. None of it shows up in any cost sheet. All of it shows up in the next quarter's shortfall conversation. The fix is not pushing medical, regulatory and legal to move faster. The fix is fewer rounds. Because the risks were caught before the first draft went out. That work happens before the visual aid ever leaves the brand manager's desk. It is the cheapest fix in pharma marketing. And almost nobody is doing it.

To view or add a comment, sign in

Explore content categories